{"generic":"Plasma","drugs":["Octaplas","Plasma"],"mono":{"0":{"id":"jtkos0","title":"Generic Names","mono":"Plasma"},"1":{"id":"jtkos1","title":"Dosing and Indications","sub":{"0":{"id":"jtkos1b4","title":"Adult Dosing","mono":"<ul><li><b>Acquired combined coagulation factor deficiency, Due to liver disease or undergoing cardiac surgery or liver transplant - Transfusion of coagulation factors:<\/b> initial, 10 to 15 mL\/kg IV resulting in 15% to 25% increase in plasma coagulation factor levels; adjust based on desired clinical response<\/li><li><b>Plasma exchange - Thrombotic thrombocytopenic purpura:<\/b> 40 to 60 mL\/kg IV for complete plasma volume replacement during plasmapheresis<\/li><\/ul>"},"1":{"id":"jtkos1b5","title":"Pediatric Dosing","mono":"efficacy and safety have not been evaluated in pediatric patients "},"3":{"id":"jtkos1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acquired combined coagulation factor deficiency, Due to liver disease or undergoing cardiac surgery or liver transplant - Transfusion of coagulation factors<\/li><li>Plasma exchange - Thrombotic thrombocytopenic purpura<\/li><\/ul>"}}},"3":{"id":"jtkos3","title":"Contraindications\/Warnings","sub":[{"id":"jtkos3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to fresh frozen plasma, plasma-derived products including any plasma protein, or any component of the product<\/li><li>IgA deficiency<\/li><li>protein S deficiency, severe<\/li><\/ul>"},{"id":"jtkos3b10","title":"Precautions","mono":"<ul><li>human plasma derivative; infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>infusion rates, high; increased risk of hypervolemia with pulmonary edema or cardiac failure; monitoring recommended<\/li><li>plasmin inhibitor (alpha2-antiplasmin), low levels; increased risk of excessive bleeding or hyperfibrinolysis; monitoring recommended for patients undergoing liver transplantation<\/li><li>thrombosis may occur; monitoring recommended<\/li><li>transfusion reactions may occur; verify ABO-blood group compatibility<\/li><li>volumes exceeding 1 mL\/kg\/min; increased risk of citrate toxicity<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jtkos3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jtkos3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jtkos5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (1% or greater), Urticaria (1% or greater)<\/li><li><b>Gastrointestinal:<\/b>Nausea (1% or greater)<\/li><li><b>Neurologic:<\/b>Headache (1% or greater), Paresthesia (1% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Hypotension, Severe<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction<\/li><li><b>Respiratory:<\/b>Respiratory arrest<\/li><li><b>Other:<\/b>Citrate adverse reaction<\/li><\/ul>"},"6":{"id":"jtkos6","title":"Drug Name Info","sub":{"0":{"id":"jtkos6b17","title":"US Trade Names","mono":"Octaplas<br\/>"},"2":{"id":"jtkos6b19","title":"Class","mono":"Blood Modifier Agent<br\/>"},"3":{"id":"jtkos6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jtkos7","title":"Mechanism Of Action","mono":"Pooled solvent- or detergent-treated human plasma is comprised of plasma proteins such as albumin, immunoglobulins, other globulins, coagulation factors, complement proteins and protease inhibitors, and is used to replace human plasma proteins.<br\/>"},"9":{"id":"jtkos9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>to thaw in water bath: thaw in outer wrapper up to 30 minutes in a circulating water bath at 30 to 37 degrees C (86 to 98.6 degrees F); may use overwrap bag if appropriate; prevent water from contaminating the entry port<\/li><li>to thaw with dry tempering system, place bag between heating plates according to the manufacturer's instructions, between 30 to 37 degrees C (86 to 98.6 degrees F); remove when thawing process is complete; may be monitored and recorded with thawing device printer or barcode scanner recommended by the device manufacturer<\/li><li>avoid shaking; do not refreeze<\/li><li>base therapy on ABO-blood group compatibility to avoid transfusion reactions<\/li><li>use an infusion set with a filter for administration<\/li><\/ul>"},"10":{"id":"jtkos10","title":"Monitoring","mono":"<ul><li>aPTT, prothrombin time (PT), and specific coagulation factors; during therapy for response<\/li><li>achievement of hemostasis may indicate efficacy<\/li><li>signs and symptoms of pulmonary edema or cardiac failure; during therapy, especially with high infusion rates<\/li><li>signs of excessive bleeding in liver transplant patients<\/li><li>thrombosis in patients at risk (eg, low levels of Protein S)<\/li><\/ul>"},"13":{"id":"jtkos13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report symptoms of thrombosis, pulmonary edema, or cardiac failure.<\/li><li>Tell patient to immediately report symptoms of citrate toxicity (eg, paresthesia, fatigue, muscle spasms).<\/li><li>This drug may cause headache, nausea, or pruritus.<\/li><li>Instruct patient to report symptoms of flu-like or other viral infections, as the product is made from human plasma and may carry a small risk of transmitting infectious agents (eg, viruses and theoretically, Creutzfeldt-Jakob disease agent).<\/li><\/ul>"}}}